Siemens PLM Software’s STAR-CCM+ software, version 11.06, enhances simulation of bio/pharmaceutical processes.
Image courtesy of Siemens
Siemens PLM Software, a business unit of the Siemens Digital Factory Division, released the latest version of STAR-CCM+ software, version 11.06, for simulating equipment designs, including those of bio/pharmaceutical process equipment. For example, for applications such as multiphase flow through nozzles and orifices, bubbly flow, or counter-gravity flow, the Adaptive Multiple Size Group Population Balance (A-MUSIG) allows users to accurately model flows where the dispersed phase of bubbles, droplets, or particles has a varied population in terms of size. For simulations using the discrete element method (DEM), such as filtration or fluidized beds, the new software has a source smoothing technique that automatically smooths and coarsens the underlying computational fluid dynamics (CFD) mesh to make it more appropriate for DEM calculations. This provides the benefit of shortening the computational time of DEM simulations. Other features include a coarse grain DEM model, a clift drag force model and a compatibility with conduction heat transfer model. A Eulerian granular model allows maximum solid viscosity control, and a large-scale interface (LSI) model allows interface sharpening.
The new Simulation Tree Comparison feature allows side-by-side comparison of the simulation setup from two different cases. Users can easily identify differences or variations from best practices, saving time in checking their simulation setup.
Source: Siemens
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.